News of two blockbuster deals on July 29 could end up paying off for New York-based Guggenheim Partners, whose mergers and acquisitions advisory arm is working on both transactions.

Guggenheim Securities, the firm’s investment banking and capital-markets unit, was named as an adviser to Pfizer, the US pharmaceutical company, on the planned merger of its off-patent drug business, Upjohn, with Mylan.